Transient reactivation of occult hepatitis B virus infection despite lamivudine prophylaxis in a patient treated for non-Hodgkin lymphoma

Gilda Tonziello; Marintonietta Pisaturo; Antonello Sica; Maria Giovanna Ferrara; Caterina Sagnelli; Giuseppe Pasquale; Evangelista Sagnelli; Salvatore Guastafierro; Nicola Coppola

doi:10.1007/s15010-012-0305-y

Transient reactivation of occult hepatitis B virus infection despite lamivudine prophylaxis in a patient treated for non-Hodgkin lymphoma

Infection. 2013 Feb;41(1):225-9. doi: 10.1007/s15010-012-0305-y. Epub 2012 Aug 2.

Authors

Gilda Tonziello¹, Marintonietta Pisaturo, Antonello Sica, Maria Giovanna Ferrara, Caterina Sagnelli, Giuseppe Pasquale, Evangelista Sagnelli, Salvatore Guastafierro, Nicola Coppola

Affiliation

¹ Department of Public Medicine, Section of Infectious Diseases, Second University of Naples, Via L. Armanni 5, 80131, Naples, Italy.

PMID: 22855434
DOI: 10.1007/s15010-012-0305-y

Abstract

A female patient with non-Hodgkin lymphoma who tested positive for surface antigen of the hepatitis B virus and negative for hepatitis B core antibody experienced a reactivation of occult HBV infection 20 months after rituximab discontinuation despite lamivudine prophylaxis covering the 4 months of rituximab administration and the subsequent 12 months.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Antiviral Agents / therapeutic use*
DNA, Viral / blood
Female
Hepatitis B / complications
Hepatitis B / drug therapy*
Hepatitis B / virology
Hepatitis B virus / physiology*
Humans
Lymphoma, Non-Hodgkin / complications
Lymphoma, Non-Hodgkin / drug therapy
Viral Load
Virus Activation

Substances

Antiviral Agents
DNA, Viral